Total Payments
$86,643
2024 Payments
$31,761
Companies
28
Transactions
278
Medicare Patients
1,291
Medicare Billing
$205,036
Payment Breakdown by Category
Other$75,030 (86.6%)
Food & Beverage$6,770 (7.8%)
Travel$4,604 (5.3%)
Education$239.54 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,180 | 20 | 67.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $16,850 | 6 | 19.4% |
| Food and Beverage | $6,770 | 230 | 7.8% |
| Travel and Lodging | $4,604 | 18 | 5.3% |
| Education | $239.54 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | $41,306 | 29 | $0 (2024) |
| Gilead Sciences, Inc. | $22,543 | 55 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19,328 | 48 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $907.75 | 36 | $0 (2024) |
| ABBVIE INC. | $563.10 | 29 | $0 (2024) |
| Janssen Biotech, Inc. | $400.31 | 14 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $316.14 | 17 | $0 (2024) |
| GENZYME CORPORATION | $217.00 | 7 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $206.79 | 8 | $0 (2024) |
| Novo Nordisk Inc | $101.94 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,761 | 83 | Mallinckrodt Hospital Products Inc. ($20,798) |
| 2023 | $23,057 | 82 | Mallinckrodt Hospital Products Inc. ($12,707) |
| 2022 | $9,221 | 59 | Mallinckrodt Hospital Products Inc. ($7,801) |
| 2021 | $638.18 | 24 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($125.28) |
| 2020 | $15.42 | 1 | Cook Medical LLC ($15.42) |
| 2019 | $4,311 | 7 | Gilead Sciences, Inc. ($4,234) |
| 2018 | $9,672 | 11 | Gilead Sciences, Inc. ($9,672) |
| 2017 | $7,968 | 11 | Gilead Sciences Inc ($7,968) |
All Payment Transactions
278 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | PREVYMIS (Drug), DIFICID | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $28.05 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.83 | General |
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/22/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,125.00 | General |
| Category: Gastroenterology | ||||||
| 11/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $117.92 | General |
| Category: Gastroenterology | ||||||
| 11/13/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.42 | General |
| 11/11/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.64 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/17/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,240.00 | General |
| Category: CRITICAL CARE | ||||||
| 10/16/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/11/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $31.00 | General |
| Category: Immunology | ||||||
| 10/10/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $104.76 | General |
| Category: CRITICAL CARE | ||||||
| 10/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Travel and Lodging | Cash or cash equivalent | $56.95 | General |
| Category: Gastroenterology | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $23.15 | General |
| 10/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.42 | General |
| 10/07/2024 | EVOKE PHARMA, INC. | GIMOTI (Drug) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Gastroenterology | ||||||
| 09/30/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $34.56 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/29/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $29.31 | General |
| Category: Rare Disease | ||||||
| 09/25/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,125.00 | General |
| Category: Gastroenterology | ||||||
| 09/25/2024 | Braintree Laboratories, Inc. | SUFLAVE (Drug), SUTAB | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: GI COLON PREP | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 423 | 629 | $330,637 | $68,090 |
| 2022 | 12 | 415 | 613 | $310,660 | $68,502 |
| 2021 | 13 | 386 | 540 | $250,210 | $60,762 |
| 2020 | 4 | 67 | 100 | $27,128 | $7,682 |
Total Patients
1,291
Total Services
1,882
Medicare Billing
$205,036
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 135 | 265 | $130,189 | $36,315 | 27.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 26 | 72 | $19,385 | $6,792 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 58 | $20,317 | $5,555 | 27.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $15,551 | $4,824 | 31.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 28 | $14,572 | $3,920 | 26.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 18 | 18 | $33,115 | $3,890 | 11.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 18 | 19 | $30,035 | $1,728 | 5.8% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 18 | 19 | $23,364 | $1,511 | 6.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 24 | $4,495 | $1,392 | 31.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 14 | 15 | $26,832 | $1,287 | 4.8% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 22 | 22 | $2,327 | $601.04 | 25.8% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 56 | 63 | $10,454 | $275.06 | 2.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 144 | 275 | $134,988 | $38,996 | 28.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 40 | 94 | $25,324 | $7,764 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 55 | $19,267 | $5,784 | 30.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $14,927 | $3,715 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $9,559 | $2,717 | 28.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 11 | 11 | $20,200 | $2,348 | 11.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 14 | $7,295 | $2,189 | 30.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $23,241 | $1,561 | 6.7% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 18 | 19 | $23,313 | $1,461 | 6.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 13 | 14 | $22,108 | $1,276 | 5.8% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 16 | 17 | $1,805 | $473.13 | 26.2% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2022 | 49 | 52 | $8,633 | $217.61 | 2.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 99 | 176 | $85,831 | $27,178 | 31.7% |
About Dr. Adam Deising, D.O
Dr. Adam Deising, D.O is a Gastroenterology healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1235285222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Deising, D.O has received a total of $86,643 in payments from pharmaceutical and medical device companies, with $31,761 received in 2024. These payments were reported across 278 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($58,180).
As a Medicare-enrolled provider, Deising has provided services to 1,291 Medicare beneficiaries, totaling 1,882 services with total Medicare billing of $205,036. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology
- Location La Jolla, CA
- Active Since 01/25/2007
- Last Updated 08/27/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1235285222
Products in Payments
- TERLIVAZ (Drug) $41,306
- XIFAXAN (Drug) $19,186
- Epclusa (Drug) $13,888
- Vosevi (Drug) $4,762
- ENTYVIO (Biological) $786.92
- DUPIXENT (Biological) $423.79
- OCALIVA (Drug) $316.14
- LINZESS (Drug) $301.16
- STELARA (Biological) $207.08
- TREMFYA (Drug) $193.23
- MAVYRET (Drug) $96.79
- VIBERZI (Drug) $93.17
- GATTEX (Drug) $85.69
- DIFICID (Drug) $80.01
- LIGAMAX (Device) $77.06
- CREON (Drug) $71.98
- IQIRVO (Drug) $70.49
- REBYOTA (Biological) $57.01
- SUCRAID (Drug) $46.09
- INJECTAFER (Drug) $40.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in La Jolla
Dr. Catherine Frenette, M.d, M.D
Gastroenterology — Payments: $672,212
Gastroenterology $672,212
Dr. Quan Nhu, M.d., Ph.d, M.D., PH.D
Gastroenterology — Payments: $498,895
Gastroenterology $498,895
Dr. Paul Pockros, M.d, M.D
Gastroenterology — Payments: $478,769
Gastroenterology $478,769
Dr. Walter Coyle, M.d, M.D
Gastroenterology — Payments: $241,005
Gastroenterology $241,005
Dr. Sushrut Thiruvengadam, M.d, M.D
Gastroenterology — Payments: $51,904
Gastroenterology $51,904
Syed Fehmi, M.d., M.s, M.D., M.S
Gastroenterology — Payments: $19,681
Gastroenterology $19,681